RTT NewsHansa Biopharma Says Idefirix Meets Primary Goal In European Post-Authorization Study
- Bias Rating
-26% Somewhat Left
- Reliability
5% ReliableLimited
- Policy Leaning
-26% Somewhat Left
- Politician Portrayal
N/A
Continue For Free
Create your free account to see the in-depth bias analytics and more.
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates.
Log In
Log in to your account to see the in-depth bias analytics and more.
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
20% Positive
- Liberal
| Sentence | Sentiment | Bias |
|---|---|---|
Unlock this feature by upgrading to the Pro plan. | ||
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
59% : Hansa Biopharma said the post-authorization study requirement for Idefirix has been fulfilled, and it plans to seek full European Union approval by the end of 2026.55% : Idefirix is conditionally approved in the European Union as a desensitization treatment for highly sensitized adult patients prior to kidney transplantation from deceased donors.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.
